The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 14, 2022. Its latest SEC filing is a CT ORDER from Jul 11, 2023.
10-Q for Q3 FY2022, filed Nov 14, 2022
The sections below describe the company as of the FY2021 annual report.
Develops medicines for addiction and drug overdose, including a licensed nasal treatment for opioid overdose, for patients, first responders, and community institutions.
10-K for FY2021, filed Mar 15, 2022Opiant Pharmaceuticals, Inc. (“we”, “our” or the “Company”) is a specialty pharmaceutical company developing medicines for addictions and…View ↗
Our longer term pipeline includes medicines in development for Alcohol Use Disorder (“AUD”), Opioid Use Disorder (“OUD”), and Acute…View ↗
We developed NARCAN® (naloxone hydrochloride) Nasal Spray (“NARCAN®”), a treatment to reverse opioid overdose. This product was conceived…View ↗
There is a large and growing addressable market for opioid overdose reversal agents driven by sales into community- based and first…View ↗
EBS pays royalties based on NARCAN sales it reports quarterly, with additional payments when sales milestones are met. NIH and BARDA provide grant and contract funding tied to eligible research costs.
10-K for FY2021, filed Mar 15, 2022
$47.8M
10-K for FY2021, filed Mar 16, 2022
$47.8M ↗
Overdose-reversal treatments reach first responders and community institutions, as well as patients through pharmacies; EBS commercializes NARCAN under a global license.
10-K for FY2021, filed Mar 15, 2022
10-K for FY2021, filed Mar 15, 2022
The Company generates a large majority of revenue from the agreement with EBS. During the year ended December 31, 2021, the Company…View ↗
Yes. It kept 6 cents of every revenue dollar as net income in FY2021 and turned 4 cents into free cash flow.
10-K for FY2021, filed Mar 16, 2022
$5.2MView ↗
10-K for FY2021, filed Mar 16, 2022
$3MView ↗
10-K for FY2021, filed Mar 16, 2022
$1.9MView ↗
8-K, filed Mar 2, 2023
Each share of Opiant Common Stock, issued and outstanding immediately prior to the Effective Time (other than Opiant Common Stock cancelled…View ↗
8-K, filed Feb 27, 2023
In accordance with the terms of Dr. Crystal’s Letter Agreement, he will be relieved of his responsibilities as Chief Executive Officer of…View ↗
Grew. Revenue grew 2.6x in 4 years, from $18.4M in FY2017 to $47.8M in FY2021, about 27% a year.
Competes with Adamis Pharmaceuticals, Adial Pharmaceuticals, Alkermes, Amphastar, Anebulo Pharmaceuticals, BioCorRx, BioDelivery Services International, Braeburn Pharmaceuticals, Emergent BioSolutions, Enalare Therapeutics, Harm Reduction Therapeutics, Hikma Pharmaceuticals, H. Lundbeck, Indivior, Nasus Pharmaceuticals, Orexo, Teva Pharmaceuticals, Kaléo, and Sandoz Pharmaceuticals
10-K for FY2021, filed Mar 15, 2022The specialty pharmaceutical industry is intensely competitive and is characterized by rapid technological progress. Certain pharmaceutical…View ↗
Loading...
